Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Mitoxantrone (GVM±R) in R/R Aggressive NHL
NCT05299164Phase 1Active, not recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- May 2022
- Primary completion
- Dec 2023
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 1, open-label trial of mitoxantrone hydrochloride liposome in non-Hodgkin lymphoma (NHL) (4 cohorts), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Maximum Tolerated Dose at 21 days. Started May 2022; status: active, not recruiting.
02
Drugs
mitoxantrone hydrochloride liposome
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT05299164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05299164.